PhaseBio Pharmaceuticals Inc (PHAS)


Stock Price Forecast

Nov. 11, 2022


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading PhaseBio Pharmaceuticals Inc chart...

About the Company

We do not have any company description for PhaseBio Pharmaceuticals Inc at the moment.

Please visit https://phasebio.com/ for more information about the company.

CEO

Jonathan Mow

Exchange

NASDAQ

Website

https://phasebio.com/

$88M

Total Revenue

50

Employees

$4M

Market Capitalization

-0.05

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $PHAS News

PhaseBio Pharmaceuticals, Inc. (PHASQ)

1y ago, source: Yahoo Finance

Overall score is calculated based on proprietary scores based on sector averages in key company indicators: fair value, dividends, innovation, hiring, and insider sentiment. Note: if you don't see ...

Reflecting on PhaseBio Pharmaceuticals' (NASDAQ:PHAS) Share Price Returns Over The Last Year

1y ago, source: AOL

That downside risk was realized by PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS) shareholders over the last year, as the share price declined 11%. That's well below the market return of 42%.

David M Mott's Net Worth

7d ago, source: Benzinga.com

Who is David M Mott? David M Mott has an estimated net worth of $2.21 Billion. This is based on reported shares across multiple companies, which include PhaseBio Pharmaceuticals Inc, Ra ...

Ravi Viswanathan's Net Worth

14d ago, source: Benzinga.com

Ravi Viswanathan has an estimated net worth of $364 Million. This is based on reported shares across multiple companies, which include RHYTHM PHARMACEUTICALS, INC., Cascadian Therapeutics, Inc ...

Elite Pharmaceuticals, Inc. (ELTP)

2d ago, source: Yahoo Finance

Elite Pharmaceuticals, Inc. (PNK:ELTP) Q3 2024 Earnings Call Transcript February 15, 2024 Elite Pharmaceuticals, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the ...

Vertex Pharmaceuticals Inc VRTX

3d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

CRVS Corvus Pharmaceuticals, Inc.

2d ago, source: Seeking Alpha

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers ...

RCKT Rocket Pharmaceuticals, Inc.

6d ago, source: Seeking Alpha

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases.

Actinium Pharmaceuticals Inc ATNM

4d ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

Madrigal Pharmaceuticals, Inc.

4mon ago, source: CNN

Madrigal Pharmaceuticals, Inc. engages on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead ...

PhaseBio Pharmaceuticals Inc. (PHASQ)

1mon ago, source: Nasdaq

We’re sorry, we are currently experiencing some issues, please try again later. Our team is working diligently to resolve the issue. Thank you for your patience and ...

PhaseBio Pharmaceuticals, Inc. (PHASQ)

1mon ago, source: Yahoo Finance

*Close price adjusted for splits.**Close price adjusted for splits and dividend and/or capital gain distributions. Loading more data ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...